Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management.

Open Forum Infect Dis · 2026 · PMC12933500 · PMID 41756205

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The ALTER trial (n = 40, 98% with HIV) suggested a nonsignificant trend toward improvement in both survival and mRS with the addition of 1200 mg/d of linezolid for 4 weeks for treatment of DS-TBM [ 37 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.